Stocks · News reference

Leerink Partners Downgrades Akebia Therapeutics to Market Perform, Announces $1 Price Target

Aug 8, 2026, 12:20 AMBenzinga Newsdesk

Leerink Partners analyst Roanna Ruiz downgrades Akebia Therapeutics (NASDAQ:AKBA) from Outperform to Market Perform and announces $1 price target.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.aiOct 27, 2026, 1:04 PM
Akebia Therapeutics Announces Positive Data from VOICE Trial of Vafseo
Akebia Therapeutics reported positive results from the Vafseo Outcomes In-Center Experience (VOICE) trial, demonstrating improved safety outcomes for dialysis patients treated with vadadustat.
AKBA
BenzingaOct 26, 2026, 1:24 PMBenzinga Newsdesk
Akebia Therapeutics Reports Data From Vafseo Outcomes In Center Experience Study At American Society Of Nephrology Kidney Week 2026 In Patients With Treated With Vadadustat
AKBA
SEC EDGAROct 23, 2026, 8:06 PMSEC EDGAR
8-K filing — Akebia Therapeutics, Inc. (AKBA)
Filed: 2026-10-23 AccNo: 0001517022-26-000075 Size: 149 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
AKBA
BenzingaSep 15, 2026, 9:49 AMBenzinga Newsdesk
BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target
BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $4 price target.
AKBA